Related Experiment Video

Updated: Apr 15, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.7K

Panobinostat: first global approval

Karly P Garnock-Jones1

  • 1Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand, dru@adis.com.

Drugs
|April 4, 2015
PubMed

Insights

Panobinostat, a histone deacetylase inhibitor, is approved for treating multiple myeloma. This cancer drug targets gene expression and chromatin structure, offering a new therapeutic option.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Histone deacetylases (HDACs) regulate gene expression and chromatin structure, making them targets for cancer therapy.
  • Panobinostat is a novel histone deacetylase (HDAC) inhibitor developed by Novartis.
  • Dysregulation of HDACs is implicated in the pathogenesis of various cancers, including multiple myeloma.

Purpose of the Study:

  • To summarize the key developmental milestones of panobinostat.
  • To highlight the regulatory approvals and clinical development of panobinostat for cancer treatment.
  • To provide an overview of panobinostat's mechanism of action as an HDAC inhibitor.

Main Methods:

  • Review of preclinical and clinical data for panobinostat.
  • Analysis of regulatory submission data for panobinostat.
  • Summary of ongoing clinical trials investigating panobinostat in various tumor types.

Main Results:

  • Oral panobinostat (Farydak®) is approved in the US in combination therapy for recurrent multiple myeloma.
  • Regulatory submissions for panobinostat combination therapy in multiple myeloma have been made in the EU and Japan.
  • Panobinostat is under investigation in diverse hematological and solid tumors.

Conclusions:

  • Panobinostat represents a significant advancement in the treatment of multiple myeloma.
  • The development of panobinostat highlights the therapeutic potential of HDAC inhibitors in oncology.
  • Panobinostat's broad clinical development indicates its potential utility across a spectrum of cancers.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K
Comprehensive Analysis of Drug Response using the FLICK Assay09:42

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

900

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
336
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.4K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
360
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
94
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.3K